Sugi Predict

Sugi Predict / Compounds / SCHEMBL3605034

SCHEMBL3605034

SCHEMBL3605034

CC(C)(O)c1csc(N)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.46
▸ NOS1 P29475 2/20 0.46
▸ TSHR P16473 2/20 0.39
▸ ALDH1A1 P00352 6/20 0.38
▸ NPC1 O15118 5/20 0.38
▸ MAPT P10636 4/20 0.38
▸ HSD17B10 Q99714 3/20 0.38
▸ GFER P55789 1/20 0.38
▸ LTA4H P09960 1/20 0.38
▸ MKNK1 Q9BUB5 1/20 0.38
▸ MKNK2 Q9HBH9 1/20 0.38
▸ GABRA5 P31644 1/20 0.37
▸ GABRB2 P47870 1/20 0.37
▸ HTT P42858 2/20 0.36
▸ LMNA P02545 2/20 0.36
▸ RAB9A P51151 3/20 0.36
▸ MEN1 O00255 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ HPGD P15428 1/20 0.35
▸ POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL77483 0.82 SMN1; SMN2 (0.50) SMN1; SMN2NOS1TSHRALDH1A1NPC1
SCHEMBL20908390 0.78 SMN1; SMN2 (0.46) SMN1; SMN2NOS1TSHRALDH1A1NPC1
SCHEMBL4965490 0.78 TSHR (0.46) SMN1; SMN2NOS1TSHRALDH1A1NPC1
SCHEMBL4255129 0.76 TSHR (0.45) SMN1; SMN2NOS1TSHRALDH1A1NPC1
SCHEMBL25308644 0.76 KDM4E (0.33) SMN1; SMN2NPC1MAPTHTTLMNA
SCHEMBL10245083 0.76 ALDH1A1 (0.40) SMN1; SMN2ALDH1A1NPC1MAPTHTT
SCHEMBL20769737 0.75 HSD17B10 (0.47) SMN1; SMN2NOS1TSHRALDH1A1NPC1
SCHEMBL20769654 0.75 TSHR (0.43) SMN1; SMN2NOS1TSHRALDH1A1NPC1
SCHEMBL8802935 0.74 CCR4 (0.30) —
SCHEMBL10223181 0.74 CCR4 (0.33) SMN1; SMN2TSHRALDH1A1NPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023217201-A2 NOVEL PYRIMIDO-HETEROCYCLIC NOVEL COMPOUND SERVING AS WEE1 INHIBITOR AND APPLICATION THEREOF 杭州德睿智药科技有限公司 2023-11-16 — — WO disclosed
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases MASARYKOVA UNIVERZITA (CZ) 2023-02-21 — — US disclosed
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases MASARYKOVA UNIVERZITA (CZ) 2023-02-21 — — US disclosed
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2022-01-06 — — US disclosed
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2022-01-06 — — US disclosed
EP-3556755-B1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES UNIV MASARYKOVA (CZ) 2021-11-17 — — EP disclosed
EP-3556755-B1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES UNIV MASARYKOVA (CZ) 2021-11-17 — — EP disclosed
US-11053234-B2 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin D synthase inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-07-06 — — US disclosed
CN-112313229-A Substituted aminothiazoles as inhibitors of nucleases 马萨里克大学 2021-02-02 — — CN disclosed
WO-2019201865-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2019-10-24 — — WO disclosed
US-20140309207-A1 NOVEL SPIROINDOLINE COMPOUND, AND MEDICINAL AGENT COMPRISING SAME KOWA COMPANY, LTD (JP) 2014-10-16 — — US disclosed
EP-2781521-A1 NOVEL SPIROINDOLINE COMPOUND, AND MEDICINAL AGENT COMPRISING SAME Kowa Company, Ltd. (JP) 2014-09-24 — — EP disclosed
US-7754743-B2 Heteroarylcarbamoylbenzene derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-07-13 — — US disclosed
CN-101712657-A heteroarylcarbamoylbenzene derivative BANYU PHARMA CO LTD 2010-05-26 — — CN disclosed
CN-100591671-C Heteroarylcarbamoylbenzene derivatives BANYU PHARMA CO LTD 2010-02-24 — — CN disclosed
US-20090018056-A1 Heteroarylcarbamoylbenzene derivatives MSD K.K. (JP) 2009-01-15 — — US disclosed
US-7432287-B2 Heteroarylcarbamoylbenzene derivative BANYU PHARMECEUTICAL CO., LTD. (JP) 2008-10-07 — — US disclosed
US-20060167053-A1 Heteroarylcarbamoylbenzene derivative MSD K.K. (JP) 2006-07-27 — — US disclosed
CN-1777589-A Heteroarylcarbamoylbenzene derivatives BANYU PHARMA CO LTD (JP) 2006-05-24 — — CN disclosed
EP-1600442-A1 HETEROARYLCARBAMOYLBENZENE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-11-30 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases RNASEH1, DNASE1, FEN1 SMN1; SMN2 104/4885NOS1 2514/4885TSHR 1512/4885
US-11053234-B2 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin D synthase inhibitors HPGDS, PTGDR, PTGER1 SMN1; SMN2 320/4885NOS1 226/4885TSHR 3838/4885
US-20090018056-A1 Heteroarylcarbamoylbenzene derivatives GCK, GCKR, KHK SMN1; SMN2 4432/4885NOS1 1424/4885TSHR 2079/4885
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES RNASEH1, DNASE1, FEN1 SMN1; SMN2 104/4885NOS1 2514/4885TSHR 1512/4885
US-20140309207-A1 NOVEL SPIROINDOLINE COMPOUND, AND MEDICINAL AGENT COMPRISING SAME GCKR, GCK, GALK1 SMN1; SMN2 3745/4885NOS1 2828/4885TSHR 1075/4885
US-20060167053-A1 Heteroarylcarbamoylbenzene derivative GCK, GCKR, GALK1 SMN1; SMN2 4329/4885NOS1 3130/4885TSHR 3647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.